Andrea Nguyen, PA-C, MS, reviews key considerations for the comprehensive management of hidradenitis suppurativa (HS), emphasizing the need for a multifactorial approach that addresses both disease activity and its broader impact on patients. Drawing from her presentation at DERM2026, she discusses the psychosocial burden of HS, high Dermatology Life Quality Index (DLQI) scores, permanent scarring, and the consequences of delayed or missed diagnosis.
Topics Covered
- Psychosocial burden and quality-of-life impact of HS
- Consequences of delayed diagnosis and permanent scarring
- Limitations of traditional Hurley staging
- Use of HiSCR and other measures for assessing treatment response
- Screening for and managing HS-associated comorbidities
- Clinical data for TNF and IL-17 inhibitors
- Emerging oral JAK inhibitors for HS
Explore Related Resources
- Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients—Part 1
- Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients—Part 2
- Key Takeaways on Managing Hidradenitis Suppurativa
